• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Safety evaluation of conditionally immortalized cells for renal replacement therapy

Bioengineer by Bioengineer
November 25, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats

IMAGE

Credit: Correspondence to: Rosalinde Masereeuw, email: [email protected]


Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats.

They demonstrate that these cells do not possess key properties of oncogenically transformed cells, including anchorage-independent growth, lack of contact inhibition and apoptosis-resistance.

Taken together, this study lays an important foundation towards bioartificial kidney development by confirming the safety of the cell line intended for incorporation.

Dr. Rosalinde Masereeuw from the Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands said, “End-stage kidney disease represents irreversible kidney failure through a variety of causes.”

Human primary proximal tubule epithelial cells have a limited life span in vitro and presenting risks, such as functional changes occurring upon culturing as well as dedifferentiation and senescence of cells.

Issues related to the use of animal-derived cells in BAK are safety concerns compromising approval for clinical application and species differences in cell behaviour.

Due to the expression of temperature-sensitive SV40T, cells can be expanded at permissive temperature of 33 C and differentiated into mature cells at non-permissive temperature of 37 C.

With this cell line the authors demonstrated the capacity of an efficient removal of uremic toxins when cells are cultured on hollow fiber membranes , thereby creating fully functional kidney tubules.

Finally, they evaluated cell transforming properties and tumorigenic potential in vivo to gain more insight into safety and suitability of these cells for applications in renal replacement therapies.

The Masereeuw Research team concluded, “by showing that ci PTEC-OAT1 do not portray fundamental characteristics of oncogenically transformed cells, do not present negative consequences of viral transductions and genomic transgene integrations, such as insertional mutagenesis, nor possess tumorigenic capacity in vivo, the present study lays an important foundation towards validating the safety of a conditionally immortalized cell line for clinical application as cell-based renal replacement therapy.”

###

Full text – http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=27152&path%5B%5D=86951

Correspondence to – Rosalinde Masereeuw – [email protected]

Keywords – bioartificial kidney, cell therapy safety, conditionally immortalized proximal tubule epithelial cells, tumorigenicity, viral integration

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @OncotargetJrnl

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957×105

[email protected]

Media Contact
Ryan James Jessup
[email protected]
800-922-0957 x105

Original Source

http://www.oncotarget.com/news/pr/safety-evaluation-of-conditionally-immortalized-cells-for-renal-replacement-therapy

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27152

Tags: cancerMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Transdermal Contraception: Advancing Reproductive Justice for Women

September 9, 2025

PCORI Grants New Patient-Centered Comparative Effectiveness Research to Enhance Informed Health Care Decisions

September 9, 2025

Early Cerebral Palsy Detection Accelerated in High-Risk Infants

September 9, 2025

Impact of Weighted Blankets on ADHD Sleep Issues

September 9, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • Physicists Develop Visible Time Crystal for the First Time

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Transdermal Contraception: Advancing Reproductive Justice for Women

Chinese Scientists Create Assembloid Model to Unravel Adenomyosis Pathogenesis

Quantum Adaptive Imaging via Biphoton Wavefront Sensing

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.